Search Within

Komal Lachhman Jhaveri

Formats
  1. Meeting Abstract (120)
  2. Journal Article (88)
  3. Review (5)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
Groups
  1. Breast Medicine Service (217)
  2. Department of Medicine (217)
  3. Solid Tumor Oncology Division (217)
  4. GSK Faculty (58)
  5. Survivorship Research (45)
  6. Epidemiology and Biostatistics (44)

More Groups

People
  1. Shanu Modi (35)
  2. Sarat Chandarlapaty (28)
  3. Pedram Razavi (25)
  4. Clifford Hudis (24)
  5. Sujata Patil (22)
  6. Gary Ulaner (18)

More People

Years
  1. 2025 (23)
  2. 2024 (34)
  3. 2023 (17)
  4. 2022 (24)
  5. 2021 (26)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (33)
  3. Annals of Oncology (22)
  4. Clinical Cancer Research (10)
  5. European Journal of Cancer (5)
  6. New England Journal of Medicine (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. American Association for Cancer Research (47)
  3. Oxford University Press (23)
  4. Elsevier Inc. (16)
  5. Springer (7)
  6. Nature Publishing Group (6)

More Publishers

Results (217)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)
    Meeting Abstract

    Turner, N. C.; Im, S. A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Thanopoulou, E.; Shankar, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts.
    Meeting Abstract

    Oliveira, M.; Accordino, M. K.; Cervantes, A.; Gambardella, V.; Hamilton, E. P.; Italiano, A.; Jhaveri, K. L.; Juric, D.; Kalinsky, K.; Krop, I. E.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world (RW) analysis of characteristics and risk of recurrence (ROR) in Black patients (pts) with HR+/HER2-early breast cancer (EBC) eligible for NATALEE
    Meeting Abstract

    Abdou, Y.; Reid, S. A.; Jhaveri, K. L.; Pegram, M. D.; Schlam, I.; Sparano, J. A.; Olumba, B. T.; Santarsiero, E. C.; Ganapathy, V.; Akdere, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Safety analyses from the phase III EMBER-3 trial
    Meeting Abstract

    O'Shaughnessy, J.; Bidard, F. C.; Neven, P.; Casalnuovo, M. L.; Aftimos, P. G.; Manich, C. S.; Harbeck, N.; Carey, L. A.; Curigliano, G.; García-Sáenz, J. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • RYZ101 ((225)Ac-DOTATATE) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2–negative, locally advanced and unresectable, or metastatic breast cancer progressing after prior therapy: The phase 1b/2 TRACY-1 study
    Meeting Abstract

    Mayer, E. L.; Miller, K.; Jhaveri, K. L.; Yeh, R.; Sakach, E.; Prasad, V.; Ferreira, D. V.; Herszdorfer, P.; Gong, L.; Li, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer: A United States Electronic Health Records database analysis
    Journal Article

    Tarantino, P.; Rugo, H. S.; Curigliano, G.; O'Shaughnessy, J. A.; Janni, W.; Jhaveri, K.; Mouabbi, J.; Brufsky, A.; Hamilton, E.; O'Regan, R.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Expert consensus on treating HR+/HER2-metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists
    Journal Article

    Rugo, H. S.; Bardia, A.; Gradishar, W. J.; Hamilton, E. P.; Hurvitz, S. A.; Jhaveri, K.; Mahtani, R.; Tolaney, S. M.
    Breast (2025)

    Fulltext@MSK | Save
  • Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: Findings from the SUMMIT basket trial
    Journal Article

    Goldman, J. W.; Bueno, A. M.; Dooms, C.; Jhaveri, K.; de Miguel, M.; Piha-Paul, S. A.; Unni, N.; Zick, A.; Mahipal, A.; Suga, J. M.; more...
    Clinical Lung Cancer (2025)

    Fulltext@MSK | Save
  • Imlunestrant with or without abemaciclib in advanced breast cancer
    Journal Article

    Jhaveri, K. L.; Neven, P.; Casalnuovo, M. L.; Kim, S. B.; Tokunaga, E.; Aftimos, P.; Saura, C.; O'Shaughnessy, J.; Harbeck, N.; Carey, L. A.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study
    Journal Article

    Bedard, P. L.; Jhaveri, K. L.; Accordino, M. K.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; more...
    European Journal of Cancer (2025)

    Fulltext@MSK | Save